NecstGen and Digi.Bio Collaborate to Improve Cell and Gene Therapy Testing
Wednesday, February 19, 2025
NecstGen and Digi.Bio have formed a collaboration to enhance testing and development in Cell and Gene Therapy. NecstGen, a non-profit CDMO, and Digi.Bio, a developer of lab-on-a-chip technology, aim to improve the understanding of modified cells, which have the potential to treat diseases but require advanced technologies due to their complexity.
The partnership utilises Digi.Bio’s platform to enable dynamic multiparametric single-cell immunoprofiling, helping to accelerate the development of Cell Therapies. As the industry continues to advance, there is a growing need for reliable testing methods to assess the effectiveness, safety, and mode of action of therapies. These evaluations are essential for regulatory approval and patient treatment.
Digi.Bio’s technology integrates laboratory processes into a single microfluidic chip, using automation, microfluidics, AI, and machine learning to analyse cell behaviour in real-time. This approach examines cell interactions, motility, and therapeutic potential. Through this collaboration, NecstGen gains access to innovative technologies that could speed up the development of Cell and Gene Therapies while improving testing capabilities.
Source: necstgen.com
